Article Details

Kinnate Doses First Patient in Phase I Trial of FGFR Inhibitor | Precision Oncology News

Retrieved on: 2022-04-18 18:52:01

Tags for this article:

Click the tags to see associated articles and topics

Kinnate Doses First Patient in Phase I Trial of FGFR Inhibitor | Precision Oncology News. View article details on hiswai: https://www.precisiononcologynews.com/cancer/kinnate-doses-first-patient-phase-i-trial-fgfr-inhibitor

Excerpt

NEW YORK – Kinnate Biopharma announced today that it has begun dosing patients in a Phase I trial of its small molecule kinase inhibitor KIN-3248.

Article found on: www.precisiononcologynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up